A new DRUG TRIALS SNAPSHOT is now available.
MEPSEVII is used to treat children and adult patients with mucopolysaccharidosis VII (also known as MPS VII or Sly Syndrome). Mucopolysaccharidosis VII is a rare, inherited disease. It is caused by a low level of an enzyme (β-glucuronidase). The lack of an enzyme causes mucopolysaccharides (long chains of sugar molecules) to build up in the tissues and organs of the body, causing progressive damage.
MEPSEVII is an enzyme replacement therapy that works by replacing the missing enzyme. MEPSEVII is given by a healthcare provider directly, into the bloodstream, through a needle in the vein, intravenous (IV) infusion every two weeks. MEPSEVII is infused over 4 hours. The amount of drug used depends on patient’s weight.